The regulatory history of peptide compounding in the United States is complex and fast-moving. This timeline covers every major event from the original 2023 restrictions through the February 2026 announcement by HHS Secretary Kennedy.
Background: How Compounding Works
Under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, licensed pharmacies can compound medications — including peptides — that are not commercially available as FDA-approved drugs. This has been a legal and legitimate part of American pharmacy practice for decades.
The FDA maintains a list of "bulk drug substances" that can and cannot be used in compounding. Category 1 substances are permitted; Category 2 substances are restricted due to identified safety concerns.
The Timeline
Pre-2023: The Peptide Compounding Era
For years, compounding pharmacies legally prepared peptides like BPC-157, Thymosin Alpha-1, and various growth hormone secretagogues for patients with valid prescriptions. This was a growing market as clinicians increasingly incorporated peptide therapy into practice.
September 2023: The FDA Adds ~17 Peptides to Category 2
The FDA took dramatic action, placing approximately 17 peptide bulk drug substances on the Category 2 list. This effectively banned compounding pharmacies from preparing these compounds, including:
- •BPC-157 (Pentadecapeptide)
- •Thymosin Alpha-1
- •Thymosin Beta-4 (TB-500)
- •CJC-1295
- •Ipamorelin
- •AOD-9604
- •GHRP-2 and GHRP-6
- •Selank and Semax
- •GHK-Cu (injectable)
- •Epitalon
- •MOTS-C
- •KPV
- •Melanotan II
- •DSIP
- •Kisspeptin-10
- •PEG-MGF
- •Cathelicidin LL-37
The stated justification: these substances presented safety concerns due to limited human clinical data, potential immunogenicity, contamination risks, and — in the case of GHRP-2 — documented adverse events including deaths.
Industry Response: Legal Challenges and Lobbying
The compounding industry pushed back aggressively:
- •Alliance for Pharmacy Compounding (A4PC): Argued the FDA overstepped its authority and lacked sufficient safety signals to justify Category 2 classification for many peptides.
- •Legal challenges: Multiple lawsuits argued the FDA's process was procedurally flawed.
- •Congressional pressure: Legislators began engaging on the issue, particularly those aligned with compounding pharmacy interests.
September 20, 2024: FDA Removes 5 Peptides from Category 2
In a significant reversal, the FDA announced that five peptides were being removed from the Category 2 list because their nominators withdrew the nominations:
- 1.AOD-9604
- 2.CJC-1295
- 3.Ipamorelin acetate
- 4.Thymosin Alpha-1 (Ta1)
- 5.Selank acetate (TP-7)
The removal was effective September 27, 2024 (seven days after the FDA published its notice). These peptides were referred to the Pharmacy Compounding Advisory Committee (PCAC) for further evaluation.
October 29, 2024: PCAC Reviews Ipamorelin
The PCAC met to evaluate Ipamorelin acetate for potential inclusion on the approved compounding list under section 503A.
December 4, 2024: PCAC Reviews CJC-1295, AOD-9604, and Thymosin Alpha-1
The PCAC evaluated three more peptides for potential inclusion on the 503A bulks list. This was a scheduled continuation of the review process initiated after the September 2024 removals.
November 10, 2025: The Harshbarger Letter
Rep. Diana Harshbarger (R-TN) — who is also a licensed pharmacist — sent a letter to HHS Secretary Robert F. Kennedy Jr. requesting that HHS exercise enforcement discretion on peptide compounding and reevaluate the remaining Category 2 restrictions.
The letter specifically named BPC-157 and five other peptides. Harshbarger's argument: the FDA's restrictions were driving patients to unregulated grey market sources, creating a worse safety situation than regulated compounding would.
Senator Tommy Tuberville (R-AL) made similar requests around the same time.
February 27, 2026: The RFK Jr. Announcement
HHS Secretary Robert F. Kennedy Jr. appeared on the Joe Rogan Experience (Episode #2461) and announced that approximately 14 of the remaining peptides on the Category 2 list would be moved to Category 1.
Kennedy's stated position: "My hope is that they're going to get moved to a place where people have access from ethical suppliers." He acknowledged that the evidence base for many of these compounds is still being gathered.
March 2026: Peptide Sciences Shuts Down
Peptide Sciences — the largest grey market research peptide vendor — voluntarily shut down operations, citing no specific reason beyond the decision being "voluntary." Independent testing by Finnrick Analytics had previously given their retatrutide an E rating (the lowest possible grade) based on 37 samples tested.
The shutdown is widely interpreted as a sign that the grey market research vendor model is no longer sustainable in the current regulatory environment.
What Comes Next
Expected Near-Term (March–July 2026)
- •30-day comment period on the proposed reclassification
- •FDA formalization of the updated Category lists
- •State pharmacy board implementation of local rules governing peptide compounding
- •Expansion of telehealth peptide clinic offerings as compounds become legally compoundable
The Bigger Picture
The peptide market is bifurcating:
- 1.Legitimate prescribed access through telehealth clinics and compounding pharmacies — growing
- 2.Grey market research vendors — shrinking under regulatory pressure
This isn't a temporary shift. The combination of political support (Harshbarger, Tuberville, Kennedy), industry lobbying (A4PC), legal challenges, and market forces (Hims & Hers acquiring peptide manufacturing) all point in one direction: peptides are moving into mainstream medicine.
The question isn't *whether* this happens — it's how fast, and whether patients will have access to reliable information to make informed decisions. That's what PeptideVerdict is here for.
This timeline will be updated as the formal FDA reclassification is published and implementation proceeds. Last updated March 7, 2026.